Market analysis articles from across Nature Portfolio

A retrospective analysis shows that the IRA will not result in a large-scale defunding of biopharmaceutical innovation.

Although investment in pharmaceutical research and development (R&D) has increased substantially in recent decades, the lack of a corresponding increase in the output in terms of new drugs being approved indicates that therapeutic innovation has become more challenging. Here, using a large database that contains information on R&D projects for more than 28,000 compounds investigated since 1990, Riccaboni and colleagues examine the factors underlying the decline in R&D productivity, which include an increasing concentration of R&D investments in areas in which the risk of failure is high.

A process for the non-arbitrary determination of obviousness based on examining actual patenting practices of large groups could improve outcomes.

The market for hepatocellular carcinoma is set to change with the recent approvals of the kinase inhibitor lenvatinib and the immune checkpoint inhibitor nivolumab, as well as the anticipated approvals of further immunotherapies.

This article discusses the market for oral anticoagulants, and how therapies in development and antidotes to existing drugs could affect the therapeutic landscape.

How many cancer cell therapies are being developed? To harmonize efforts in this arena, the Cancer Research Institute has curated a database that includes all cell therapies in development.

Immune checkpoint inhibitors are forecast to expand the market for gastroesophageal cancer drugs, which is particularly large in Asia.

This article discusses the market for chimeric antigen receptor (CAR) T cell therapies, focusing on haematological malignancies.